Relmada Therapeutics, Inc.

NasdaqGS:RLMD Stok Raporu

Piyasa değeri: US$102.6m

Relmada Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Relmada Therapeutics şirketinin kazançları yıllık ortalama -26.6% oranında azalırken, Pharmaceuticals sektörünün kazançları yıllık 0.2% oranında azaldı.

Anahtar bilgiler

-26.6%

Kazanç büyüme oranı

-8.4%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi6.0%
Gelir büyüme oranın/a
Özkaynak getirisi-141.1%
Net Marjn/a
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Relmada Therapeutics: Run Up Into Results May Resume Following This Drop

Mar 21

Here's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation

Mar 13
Here's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation

Relmada: Phase 3 Data Did Not Live Up To Phase 2 Benchmark

Jan 14

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?

Dec 04
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?

Aug 29
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?

We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

May 07
We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

Dec 15
We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

Relmada Downgraded at Truist, Guggenheim in wake of depression candidate failure

Oct 14

Relmada Therapeutics: Initiating With A Strong BUY; Key Phase 3 Short-Term Catalysts Lined Up

Sep 14

Relmada Therapeutics receives FDA fast track tag for REL-1017 to treat depression

Aug 09

We're Hopeful That Relmada Therapeutics (NASDAQ:RLMD) Will Use Its Cash Wisely

Jul 14
We're Hopeful That Relmada Therapeutics (NASDAQ:RLMD) Will Use Its Cash Wisely

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?

Feb 26
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?

4 Clinical Catalysts On Tap For Relmada In 2022

Jan 28

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?

Nov 04
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?

Our First Look At Relmada Therapeutics

Jun 28

We're Not Very Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

Jun 28
We're Not Very Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

Here's Why We're Not Too Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation

Mar 09
Here's Why We're Not Too Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation

What Percentage Of Relmada Therapeutics, Inc. (NASDAQ:RLMD) Shares Do Insiders Own?

Jan 15
What Percentage Of Relmada Therapeutics, Inc. (NASDAQ:RLMD) Shares Do Insiders Own?

Enrollment underway in Relmada Therapeutics' late-stage depression study with REL-1017

Dec 07

Relmada Therapeutics (RLMD) Investor Presentation - Slideshow

Dec 02

Relmada Therapeutics (RLMD) Investor Presentation - Slideshow

Nov 16

Gelir ve Gider Dağılımı

Relmada Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NasdaqGS:RLMD Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 240-874249
31 Mar 240-944652
31 Dec 230-994955
30 Sep 230-1124967
30 Jun 230-1294587
31 Mar 230-14447104
31 Dec 220-15748113
30 Sep 220-15345112
30 Jun 220-15745115
31 Mar 220-14340102
31 Dec 210-1263591
30 Sep 210-1123279
30 Jun 210-862957
31 Mar 210-712844
31 Dec 200-592534
30 Sep 200-432223
30 Jun 200-301812
31 Mar 200-231111
31 Dec 190-1578
30 Sep 190-1857
30 Jun 190-1757
31 Mar 190-1765
31 Dec 180-1755
30 Sep 180-1144
30 Jun 180-943
31 Mar 180-742
31 Dec 170-651
30 Sep 170-651
30 Jun 170-661
31 Mar 170-872
31 Dec 160-872
30 Sep 160-994
30 Jun 160-3106
31 Mar 160698
31 Dec 1506910
30 Sep 15014810
30 Jun 150-2198
31 Mar 150-55199
31 Dec 140-46174
30 Sep 140-56166
30 Jun 140-28135
31 Mar 140-1325

Kaliteli Kazançlar: RLMD şu anda kârlı değil.

Büyüyen Kar Marjı: RLMD şu anda kârlı değil.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: RLMD kârlı değildir ve zararlar son 5 yılda yılda 26.6% oranında artmıştır.

Büyüme Hızlandırma: RLMD 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: RLMD kârlı olmadığından, geçmiş yıl kazanç büyümesinin Pharmaceuticals sektörüyle ( 54.6% ) karşılaştırılması zorlaşıyor.


Özkaynak Getirisi

Yüksek ROE: RLMD hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -141.1% ) sahiptir.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin